Company Profile
Lucid Diagnostics Stock Price, News & Analysis
- Ticker:
- LUCD
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- United States
Stock performance
1.00 USD (-6.54%)
Close
Last updated: July 10, 2026 at 00:00
190.77M USD
Market cap
Why the stock is moving
LUCD is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Lucid Diagnostics is a diagnostics and life sciences tools company focused on testing, assay adoption, and workflow utility, with investors watching recurring demand and product mix as much as clinical news flow.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Lucid Diagnostics is followed within the diagnostics and tools universe for its exposure to customer demand and adoption cycles.
Business Model Characteristics
Lucid Diagnostics is a commercial-tools story where install base, recurring demand, and product adoption drive the narrative more than one-off clinical events.
Position Within the Biotechnology Landscape
Compared with therapeutic biotech names, Lucid Diagnostics sits on a different part of the landscape where utilization, customer demand, and product refresh tend to matter more than binary FDA events.
Future catalysts
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Zimmer Biomet Names Chintan Desai President of Asia Pacific Region
ZBH · Source: Zimmer Biomet
- 02
- 03
Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
ENLV · Source: Enlivex Therapeutics
- 04
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results
ZBH · Source: Zimmer Biomet
- 05
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
BMY · Source: BMYBristol-Myers Squibb Company
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Lucid Diagnostics (LUCD)?
Lucid Diagnostics (LUCD) most recently closed at 1.00 USD, a -6.54% move versus the previous session.
What is the market cap of Lucid Diagnostics (LUCD)?
Lucid Diagnostics currently has a market capitalization of 190.77M USD on BioPharmSignal.
What does Lucid Diagnostics do?
Lucid Diagnostics is a diagnostics and life sciences tools company focused on testing, assay adoption, and workflow utility, with investors watching recurring demand and product mix as much as clinical news flow.
On which exchange is LUCD stock listed?
Lucid Diagnostics (LUCD) is associated with NASDAQ, United States, Biotechnology.
What is Lucid?
Lucid Diagnostics is a diagnostics and life sciences tools company focused on testing, assay adoption, and workflow utility, with investors watching recurring demand and product mix as much as clinical news flow.
Which conditions is Lucid Diagnostics targeting with Lucid?
Lucid Diagnostics is a diagnostics and life sciences tools company focused on testing, assay adoption, and workflow utility, with investors watching recurring demand and product mix as much as clinical news flow.
What is Diagnostics?
Lucid Diagnostics is a diagnostics and life sciences tools company focused on testing, assay adoption, and workflow utility, with investors watching recurring demand and product mix as much as clinical news flow.